AI Steps In to Rescue Personalized Neoantigen Cancer Vaccines From Costly Guesswork

Personalized neoantigen cancer vaccines have long been one of the most seductive promises in precision oncology: a therapy built from a patient’s own tumor mutations, designed to train the immune system to hunt cancer cells with surgical specificity. A comprehensive review published in the Journal of Biomedical Science now maps, in unusual detail, both how far this field has traveled and how far it still has to go. The authors, led by researchers at Taipei Medical University together with collaborators at the University of Oxford, argue that artificial intelligence is becoming the connective tissue of the entire vaccine pipeline, from the first sequencing run to the lipid nanoparticle that finally carries the vaccine into a patient’s arm.

The biological logic behind neoantigen vaccines is compelling. Neoantigens arise from somatic mutations that exist only in tumor cells, which means the immune system has not been trained to tolerate them, and the risk of off-target autoimmunity is theoretically low. Advances in next-generation sequencing, HLA typing, immunopeptidomics and synthetic vaccine platforms have made it feasible to sequence a patient’s tumor, identify candidate mutation-derived antigens and manufacture an individualized vaccine in a matter of weeks. Early clinical studies have now established feasibility, safety and immunogenicity across a striking range of solid tumors, including melanoma, pancreatic ductal adenocarcinoma, hepatocellular carcinoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma, using platforms that span mRNA, peptide, DNA, viral vector and dendritic cell technologies.

The clinical momentum is real. In the phase 2b KEYNOTE-942 trial, the individualized mRNA vaccine mRNA-4157, known as V940, combined with pembrolizumab achieved 18-month recurrence-free survival of 79 percent versus 62 percent with pembrolizumab alone in resected melanoma, a hazard ratio of 0.561, with no grade 4 or 5 adverse events attributed to the vaccine. In pancreatic cancer, one of the hardest immunologic targets in oncology, responders to the personalized RNA vaccine autogene cevumeran showed markedly prolonged recurrence-free survival compared with non-responders, with a median not yet reached versus 13.4 months. A phase 3 trial in resected high-risk melanoma, INTerpath-001, is now enrolling roughly 1,089 patients, a sign that the field is moving from proof of concept toward pivotal testing.

Yet beneath these headline numbers lies an uncomfortable attrition problem that the review dissects stage by stage. Only a small fraction of the mutations identified in a tumor ever become genuinely immunogenic vaccine targets. In the autogene cevumeran pancreatic cancer trial, just 11 percent of the administered vaccine neoantigens, 25 out of 230, elicited measurable T-cell responses. In the NeoVax melanoma study, roughly 60 percent of vaccine neoantigens induced CD4-positive T-cell responses but only about 16 percent triggered CD8-positive cytotoxic T cells. A recent systematic evaluation found that only around 22 percent of predicted neoepitopes are actually presented on HLA molecules. Each false positive dilutes the effective immunogenic content of a vaccine that has limited room for passengers.

The root of the problem is that antigen presentation is a multi-step biological process, involving proteasomal cleavage, TAP-mediated transport and peptide-HLA loading, that most computational pipelines compress into a single binding-affinity prediction. Even when a peptide is presented, whether it provokes a functional T-cell response depends on the three-dimensional docking geometry between the peptide-HLA complex and a cognate T-cell receptor, governed by molecular flexibility and peptide conformation that sequence-based models capture poorly. Compounding matters, the scarcity of paired TCR-peptide-MHC datasets and the staggering diversity of the TCR repertoire make generalization across patients extraordinarily difficult. Manufacturing timelines, typically seven to eight weeks for peptide and viral vector platforms, add a further constraint, since tumors can evolve while the vaccine is being built.

This is where the review sees artificial intelligence earning its place, not as a replacement for experiments but as a way to narrow enormous biological and chemical search spaces. At the discovery stage, machine learning frameworks now integrate genomic, transcriptomic and mass spectrometry-based proteomic data to prioritize candidates with multi-layer evidence of expression and presentation. Tools such as ProGeo-neo combine proteomics with patient-specific genomic profiles to confirm protein-level expression, while ImmuneMirror merges whole-exome and RNA sequencing data, and modular workflows like TIminer and pVACtools automate reproducible end-to-end immunogenomic profiling. The authors also highlight the growing importance of noncanonical antigens, derived from alternative open reading frames, aberrant splicing, intron retention, fusion transcripts, circular RNA products and endogenous retroviral elements, some of which may be shared across patients and could inform semi-shared vaccine strategies.

Presentation prediction is where measurable gains have been most convincing. Pan-allelic tools such as NetMHCpan integrate eluted ligand data with binding affinities, and MHCflurry 2.0 folds antigen-processing features into neural network models, achieving an area under the curve of roughly 0.911 for binding classification in a benchmark of 18 predictors across 32 HLA alleles. Newer architectures such as CapHLA jointly model class I and class II presentation, and protein language model-based approaches like MUNIS improve prioritization of presented epitopes. The review also makes a pointed case for CD4-positive T cells, which clinical studies have repeatedly activated, sometimes more frequently than CD8 responses, arguing that HLA class II prediction, despite its computational challenges from open binding grooves and variable peptide lengths, deserves far more attention in vaccine design.

At the T-cell recognition frontier, deep learning is pushing into structure. AlphaFold-based modeling of peptide-HLA and TCR-peptide-HLA complexes can discriminate true target epitopes from decoys, while tools such as NetTCR-2.0, DeepTCR, TRAP and SageTCR integrate paired TCR sequences and three-dimensional structural features to predict receptor binding. Benchmarking studies, however, consistently show that these models remain strongly data-dependent and often fail to generalize to unseen epitopes, so the authors position them as prioritization and hypothesis-generating tools rather than definitive immunogenicity predictors. Downstream, AI is also reshaping formulation science: the AGILE platform uses deep learning-guided screening to identify ionizable lipids for mRNA delivery, and the LiON framework applies message-passing neural networks to large lipid nanoparticle datasets, narrowing chemical design spaces before any wet-lab testing begins.

To tie these threads together, the authors propose an evidence-weighted, closed-loop decision-gate framework spanning six stages: candidate generation, tumor relevance filtering, HLA presentation evidence, immunogenicity refinement, portfolio-level selection, and manufacturability and clinical delivery, with post-vaccination immune monitoring data fed back to refine future models. They stress that repertoire size should reflect biologically meaningful coverage rather than numerical abundance, since no clinically validated optimal neoantigen count exists. On the regulatory front, the UK’s Medicines and Healthcare products Regulatory Agency has released draft guidance for individualized mRNA cancer immunotherapies, in which AI selection algorithms may qualify as Software as a Medical Device, requiring Good Machine Learning Practice, transparent pipelines, version tracking and barcode-based traceability linking genomic data to the administered dose. The review’s bottom line is measured but optimistic: AI will not conjure effective cancer vaccines on its own, but embedded within rigorous experimental validation, scalable manufacturing and evolving regulatory oversight, it may finally make personalized neoantigen vaccination a reproducible pillar of precision oncology.

Subject of Research: The application of artificial intelligence across the translational development pipeline of personalized neoantigen cancer vaccines, including neoantigen discovery, HLA presentation prediction, T-cell recognition modeling and formulation optimization.

Article Title: Artificial intelligence for translational personalized neoantigen cancer vaccine development

Article References: Artificial intelligence for translational personalized neoantigen cancer vaccine development. (n.d.). https://doi.org/10.1186/s12929-026-01286-3

Image Credits: AI Generated

DOI: 10.1186/s12929-026-01286-3

Keywords: neoantigen cancer vaccine, artificial intelligence, personalized immunotherapy, HLA presentation, T-cell receptor, lipid nanoparticle, mRNA vaccine, precision oncology, immunopeptidomics, machine learning, cancer immunotherapy, translational oncology